By 2017, two forces were reshaping the roadmap. First, the hybrid stack was hitting BLE reliability walls as device firmwares diversified, NovoPen 6, NovoPen Echo Plus, Ascensia Contour Plus One, AccuChek Guide, and multiple Medtronic pumps each had their own edge cases. Second, the sales team was losing deals to competitors with near-native UX.

We made the call to rewrite the mobile app in React Native rather than go fully native, a nine month bet that preserved a single codebase while recovering a large share of BLE connection failures within the first release.

On mobile, we migrated to React Native 0.59, introduced Redux for predictable state management and React Navigation for cross-platform routing, and added D3.js for interactive glucose trend charts. We expanded BLE coverage to 50+ devices and layered manufacturer REST APIs on top, Dexcom G5, Abbott FreeStyle Libre, and Medtronic MiniMed Connect, so we were no longer dependent on BLE alone for continuous data. Apple HealthKit and Google Fit were added to pull in activity and nutrition context.

On the backend, we re-platformed to Node.js 10 with NestJS microservices, split data between PostgreSQL 10 for transactional records and MongoDB 3.6 for unstructured device telemetry, and moved to AWS IoT Core with MQTT for real-time sync. The biggest unlock was the AI-assisted insights module, Python 3.7 with scikit-learn on AWS Lambda, which gave clinicians the first version of automated pattern detection for hypo/hyperglycemic trends.

This phase is what took the product from “useful app” to “platform clinicians depend on.”